Macrophage Pharma
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
59-60 Thames St, Windsor, Berkshire, SL4...Website
www.macrophagepharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Macrophage Pharma
Macrophage Pharma Limited (MPL) is developing transformative first in class small molecule therapeutics that precisely control or enhance immune responses across disease indications. Utilizing MPL's proprietary Esterase Sensitive Motif technology (ESM TM), its first in class therapeutics target the innate immune system in a highly selective manner. The ESM platform together with expanded variants of this foundation technology in evolution within MPL, are designed to deliver small molecule drugs selectively, not only to macrophages but also to other cell types expressing the relevant carboxylesterase isoform. The Company's R&D pipeline is focused on the targeting of key regulatory proteins in chronic inflammation-inducing pathways, such as necroptosis, pyroptosis and inflammasome to address unmet medical need. The Company was founded by the CRT Pioneer Fund (CPF) and is backed by CPF, Aglaia Oncology Fund II, Novo Holdings A/S and M Ventures.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Macrophage Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Macrophage Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Macrophage Pharma launches new products
Earning: See what the market has to say on Macrophage Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Macrophage Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Macrophage Pharma
Funding: Get notified immidiatlly once Macrophage Pharma has new funding data
Macrophage Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Macrophage Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Macrophage Pharma financials insights
Gather financial insights about Macrophage Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$11.2M
Macrophage Pharma News & Media
Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer
WINDSOR, England, June 1, 2021 /PRNewswire/ -- Macrophage Pharma Limited ('MPL'), a company focused on the discovery and early stage development of highly novel small molecule therapeutics with the potential to transform outcome in inflammation, autoimmune disease and cancer through...Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer
Macrophage Pharma Limited ("MPL"), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprogramming of macrophage function to combat cancer and other diseases, announced today that it has appointed Venkat Reddy PhD as Chief Scientific Officer (CSO) and David Moffat PhD, MPL co-founder and former director of chemistry, as Chief Technology Officer (CTO).Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer
WINDSOR, England, Jan. 9, 2020 /PRNewswire/ -- Macrophage Pharma Limited ("MPL"), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprogramming of macrophage function to combat cancer and other...Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors
WINDSOR, England, Sept. 26, 2019 /PRNewswire/ -- Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Macrophage Pharma
Sign Up For FreeTo access detailed company insights
Macrophage Pharma Limited (MPL) is developing transformative first in class small molecule therapeutics that precisely control or enhance immune responses across disease indications. Utilizing MPL's proprietary Esterase Sensitive Motif technology (ESM TM), its first in class therapeutics target the innate immune system in a highly selective manner.... Read More
